CORE Biomedicine Raises $21M Across Boston, Tokyo and Suzhou for AI-Guided Precision Oncology

CORE Biomedicine has closed a $21 million Series A to advance a new class of precision cancer therapeutics — and its structure is as notable as its science, spanning Boston, Tokyo and Suzhou in a genuinely tri-national build, according to BioSpace and the company's announcement.

The round was co-led by UTokyo Innovation Platform and Elikon Venture, with participation from InnoPinnacle Fund, Mitsubishi UFJ Capital, Suzhou Capital Group, CD Capital, YuanBio Venture Capital, Vision Incubate and Root Venture Partners. Alongside the financing, the company's Japanese subsidiary secured a grant from AMED, the Japan Agency for Medical Research and Development, and CORE separately signed an exclusive licensing agreement with Eisai for precision oncology programs.

Beyond genomics

Founded by former leaders of H3 Biomedicine, CORE is pursuing what it calls lineage-based precision medicine: rather than targeting a tumor's genetic mutations alone, it aims at the core biological pathways that define a cancer cell's identity — the lineage programs that determine what a cell is, not just which genes are broken. It is a bet that the next generation of durable cancer drugs will be designed by understanding cell fate, a domain where machine-learning models of gene-regulatory networks and single-cell data have become indispensable tools.

The Asia-anchored biotech model

CORE is a template for a rising species of biotech: capital, talent and clinical infrastructure pooled across the US, Japan and China rather than concentrated in one hub. UTokyo's fund brings academic pipeline and non-dilutive AMED money; Suzhou's capital and manufacturing base bring cost and scale; the Boston headquarters brings dealmaking proximity to pharma and the Eisai partnership.

That structure is partly strategic and partly defensive. Cross-border biotech spreads regulatory exposure, taps multiple national funding pools, and hedges the geopolitical risk of being purely US- or China-based at a moment when both governments are tightening scrutiny of the other's involvement in strategic technologies. For a $21 million Series A, assembling a syndicate that reaches from UTokyo to Suzhou to Cambridge is an unusual amount of institutional coordination — and a sign of how the economics of drug discovery increasingly favor those who can knit the ecosystems together.

What's next

The funds will carry CORE's lead programs through discovery and into early clinical development. The near-term proof points to watch are preclinical data validating the lineage-targeting thesis and whether the Eisai partnership expands beyond its initial scope — the kind of pharma endorsement that, for a young oncology company, matters more than any single funding milestone.